A breakthrough in photobiomodulation therapy for eye health —  at John Rose Eye Care

If you or a loved one has been diagnosed with dry Age-related Macular Degeneration (AMD) — or you are at risk and looking for proactive, private eye care in Richmond, Barnes, Surbiton, London or across Surrey — we invite you to discover a world-first, clinically proven treatment for the number one cause of blindness today, available  at John Rose Eye Care in Kingston upon Thames, London.

John Rose was the  first optometrist in the world in 2019 to offer Valeda™ Light Delivery System (LDS) – an FDA-cleared, CE-marked, non-invasive photobiomodulation (PBM) therapy for patients suffering with dry AMD.

 

👁️ Understanding AMD: Dry vs Wet

Age related Macular Degeneration (AMD)  is the leading cause of vision loss in people over 50 in the UK.

• Dry AMD (atrophic): Caused by gradual thinning of the macula; progresses slowly but can lead to severe vision impairment. Valeda Light Delivery system using Photobiomodulation for eye health is specifically designed to treat this form.
• Wet AMD (neovascular): Characterised by abnormal blood vessel growth; progresses rapidly and typically treated with injections.

While wet AMD has long had injectable treatments, dry AMD has, until recently, lacked a proven intervention. Valeda Light Delivery System  treatment is now available for dry AMD. It is a world’s first.

 

🕒 The Importance of Monitoring & Early Intervention

Timely assessment and diagnosis are essential. At John Rose Eye Care, we offer the Platinum Spectralis AI Comprehensive Eye Examination, which includes:

• Advanced OCT scanning
• Retinal imaging
• Microperimetry
• AI-assisted AMD progression tracking

If caught early, non-invasive therapy with Valeda can slow or reverse functional decline, improving visual outcomes.

🌟 What Is Valeda™ and Photobiomodulation Therapy?

Valeda™ Light Delivery System, developed by LumiThera Inc., uses carefully selected wavelengths of blue, red, and near-infrared light to stimulate cellular energy production, reduce inflammation, and improve function in retinal cells affected by AMD.

This non-invasive AMD treatment  harnesses the power of photobiomodulation (PBM) – a scientifically validated therapy used across medical fields – now applied with precision for eye health and dry AMD treatment.

 

🔬 Proven Results from Clinical Trials

The most recent results from the LIGHTSITE IIIb extension trial show continued vision improvement in dry AMD patients treated with Valeda™:

“Patients showed statistically significant sustained and extended vision improvement following Valeda treatment.”

— LumiThera Inc., Full clinical trial results here

These results support earlier studies that demonstrated enhanced visual acuity, improved contrast sensitivity, and slower progression of dry AMD.

 

🧬 About LumiThera Inc.

LumiThera Inc. is a pioneering US-based medical device company dedicated to treating acute and chronic ocular diseases using photobiomodulation therapy. Their focus is on non-invasive treatment options for vision preservation and improvement.

Key milestones:

• 2017: Initial development of Valeda LDS begins
• 2018: CE mark granted for use in Europe
• 2021: FDA clearance granted in the U.S. following successful trials
• 2024-2025: LightSite IIIb extension study confirms sustained vision benefits
• John Rose Eye Care becomes the world’s first clinical optometry site to offer Valeda therapy

 

📍 Serving Surrey, Richmond, Barnes & Surbiton, Surrey and surrounding areas

Patients from across Richmond, Barnes, Surbiton, and Surrey choose John Rose Eye Care for:

• Personalised, private eye health solutions
• Industry-leading diagnostic technology
• Access to FDA approved, clinically trialled proven treatments like Valeda LDS – the only non-invasive treatment using photobiomoduation for dry AMD

We welcome both new AMD patients and those at risk who want the highest standard of preventive care.

📄 FAQ: Age-Related Macular Degeneration (AMD)

Q: What are early signs of AMD?
A: Blurred central vision, difficulty reading, trouble with contrast, or seeing straight lines as wavy.

Q: Is AMD curable?
A: While there is no “cure,” treatments like Valeda can significantly improve vision and slow progression, especially in dry AMD.

Q: How is Valeda different from eye injections?
A: Valeda is non-invasive, painless, and drug-free. It works by stimulating natural cellular repair mechanisms using light.

Q: How often is the treatment?
A: The initial protocol typically includes three sessions per week for three to four weeks. Ongoing maintenance may be advised based on your condition.

Q: Who is eligible for Valeda?
A: Patients with diagnosed dry AMD. A comprehensive eye exam is required to confirm eligibility.

 

💡 Take Action Today

Whether you have recently  been diagnosed with AMD, have a loved one, family member or friend who has AMD or a history of AMD;  or want peace of mind with a comprehensive AMD assessment, John Rose Eye Care offers expertise, technology, and the most advanced non-invasive AMD treatment available globally.

📞 Book Your Dry AMD Consultation Today

WhatsApp for more information and a short intro to AMD therapy 07572 753 023 

Call: 020 8549 5060
Visit: johnroseeyecare.co.uk
Location: 1 Eden Street Kingston upon Thames, KT1 1JH
Serving Richmond • Barnes • Surbiton • Surrey London, Epsom, Teddington, Twickenham and surrounding areas

WhatsApp 07572 753 023